PPP1R13L and neoplasm: A more complete understanding of genetic and epigenetic mechanisms underlying aberrant expression of WT p53 inhibitor iASPP in human tumors, and detailed studies on iASPP function in various aspects of tumor progression, including EMT, stemness and metastasis, can provide a basis for new potential therapeutic applications in WT p53-containing tumors.